Emerging Invasive Fungal Infections in Critically Ill Patients

Emerging Invasive Fungal Infections in Critically Ill Patients: Epidemiological Trends, Clinical Features and Outcomes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04647539

Acronym

EIFI

Enrollment

Registered

2020-12-01

Start date

2006-01-01

Completion date

2020-11-23

Last updated

2020-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fungal Infection, ICU Acquired Weakness

Keywords

Emergind invasive fungal infection, mucormycosis, ICU

Brief summary

Rationale: Beside Candida and Aspergillus, emerging invasive fungal infections (EIFIs) are increasing in intensive care setting and are associated with high morbidity and mortality. However, data are scarce, particularly in ICU settings and for EIFIs other than mucormycosis. Objectives: to describe epidemiological trends and clinical features of EIFIs in intensive care units (ICU) and to assess their outcome. Methods: All records of adult patients diagnosed with an EIFI in a medical ICU between 2006 and 2019 were analyzed retrospectively. In-ICU mortality was assessed, then factors associated with mortality were identified. Survival at day-90 was calculated by the Kaplan-Meier method.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

\- Adults (≥ 18 years old) with at least 1 positive culture for molds other than candida and aspergillosis

Exclusion criteria

\- Age \< 18, pregnancy

Design outcomes

Primary

Measure	Time frame	Description
mortality	at ICU admission	mortality

Secondary

Measure	Time frame	Description
Mucormycosis	at ICU admission	Mucormycosis

Countries

France

Outcome results